Access Bio, Inc. Logo

Access Bio, Inc.

Develops and manufactures rapid diagnostic tests for infectious diseases for global health.

950130 | KO

Overview

Corporate Details

ISIN(s):
KR8840090003
LEI:
Country:
United States of America
Address:
65 Clyde Road Suite A, Somerset NJ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Access Bio, Inc. is a biotechnology company dedicated to the prevention and early diagnosis of infectious diseases. It engages in the research, development, manufacturing, and marketing of in vitro rapid diagnostic tests (IVD), biosensors, and molecular diagnostic products. The company is a key partner in global health, recognized for its comprehensive portfolio of tests for diseases such as malaria, HIV, HPV, and COVID-19. Through its products, including the CareStart™ line, Access Bio focuses on providing high-quality, accessible diagnostic solutions to combat serious health threats worldwide, particularly in developing nations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-08-18 00:00
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내 )
Korean 3.0 KB
2025-08-14 00:00
[기재정정]사업보고서 (2024.12)
Korean 2.8 MB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 3.1 MB
2025-08-14 00:00
반기또는분기매출액미달사실발생
Korean 6.0 KB
2025-08-14 00:00
기타시장안내 (상장적격성 실질심사 관련)
Korean 3.2 KB
2025-08-14 00:00
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-05-20 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 26.3 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-07 00:00
주식등의대량보유상황보고서(일반)
Korean 88.3 KB
2025-03-26 00:00
정기주주총회결과
Korean 28.5 KB
2025-03-26 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.6 KB
2025-03-18 00:00
감사보고서제출
Korean 26.7 KB
2025-03-18 00:00
사업보고서 (2024.12)
Korean 2.8 MB
2025-03-11 00:00
주주총회소집결의
Korean 15.7 KB

Automate Your Workflow. Get a real-time feed of all Access Bio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Access Bio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Access Bio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Talk to a Data Expert

Have a question? We'll get back to you promptly.